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The autosomal dominant mutation in the human
aB-crystallin gene inducing a R120G amino
acid exchange causes a multisystem, protein
aggregation disease including cardiomyopa-
thy. The pathogenesis of cardiomyopathy in
this mutant (hR120GCryAB) is poorly under-
stood. Here, we show that transgenic mice
overexpressing cardiac-specific hR120GCryAB
recapitulate the cardiomyopathy in humans and
find that the mice are under reductive stress.
The myopathic hearts show an increased recy-
cling of oxidized glutathione (GSSG) to reduced
glutathione (GSH), which is due to the aug-
mented expression and enzymatic activities of
glucose-6-phosphate dehydrogenase (G6PD),
glutathione reductase, and glutathione peroxi-
dase. The intercross of hR120GCryAB cardio-
myopathic animals with mice with reduced
G6PD levels rescues the progeny from cardiac
hypertrophy and protein aggregation. These
findings demonstrate that dysregulation of
G6PDactivity isnecessary andsufficient for mal-
adaptive reductive stress and suggest a novel
therapeutic target for abrogating R120GCryAB
cardiomyopathy and heart failure in humans.
INTRODUCTION
Protein aggregation skeletal myopathies and cardiomyop-
athies are caused by mutations in aB-crystallin (CryAB,
HSPB5) or desmin and are characterized by protein mis-
folding and large cytoplasmic aggregates (Dalakas et al.,2000; Goldfarb et al., 1998; Vicart et al., 1998). CryAB,
a small MW heat shock protein (Hsp) and molecular chap-
erone, is abundantly expressed in the ocular lens, heart
and skeletal muscle (Kappe et al., 2003). In striated tis-
sues, CryAB prevents the aggregation of client proteins
such as desmin, an intermediate filament cytoskeletal pro-
tein, thus maintaining muscle integrity and stress toler-
ance (Christians et al., 2002; Xiao and Benjamin, 1999).
When either desmin or CryAB is mutated, both CryAB
and desmin accumulate in dense granulomatous aggre-
gates, hence the term desmin-related myopathy (DRM)
(Dalakas et al., 2000; Goldfarb et al., 2004). The mecha-
nisms underlying protein misfolding diseases are poorly
understood but defining the pathogenesis of DRM might
uncover new pathways as potential targets for therapeu-
tic interventions against heart failure (Benjamin and
Schneider, 2005).
Several disease-causing mutations of CryAB have been
identified (Liu et al., 2006; Pilotto et al., 2006). The R120G
mutation of hCryAB causes an autosomal dominant, mul-
tisystem disorder that includes cardiomyopathy (Fardeau
et al., 1978; Vicart et al., 1998). Earlier studies reported the
effects of hR120GCryAB on the integrity of protein struc-
ture (Kumar et al., 1999), in vitro chaperone-like activity
(Bova et al., 1999), propensity for aggregation with inter-
mediate filaments and increased instability toward heat-
induced protein denaturation (Perng et al., 1999). In
addition, misfolded proteins such as R120GCryAB are im-
portant stress signals for triggering adaptive mechanisms
such as heat shock protein gene expression (Christians
et al., 2002). Protein misfolding exposes hydrophobic
surfaces (Bukau et al., 2006; Gething and Sambrook,
1992) and many Hsp chaperones are recruited to repair
damaged proteins, enhance protein quality control, accel-
erate protein degradation and/or mitigate potential cata-
strophic events (Christians et al., 2002; Mehlen et al.,
1996; Xiao and Benjamin, 1999). In particular, Hsp25Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 427
overexpression increases GSH content and confers resis-
tance to oxidative stress in L929 cells (Baek et al., 2000;
Mehlen et al., 1996) whereas Hsp25 downregulation,
linked to GSH depletion, increases oxidative stress in
vivo (Yan et al., 2002).
Redox equilibrium is essential for many biological pro-
cesses (Hansen et al., 2006). Oxidative stress, which con-
sumes reducing equivalents (i.e., decreased GSH/GSSG
ratio), has been often implicated in numerous cardiac
diseases but it is possible that an inverse imbalance can
provoke reductive stress (i.e., increased GSH/GSSG
ratio), which could have similar deleterious effects. Re-
ductive stress has been elegantly demonstrated in lower
eukaryotes (Simons et al., 1995; Trotter and Grant,
2002), but this has not been formerly demonstrated in
mammals and/or disease states (Chance et al., 1979).
Transgenic mouse models recapitulating defined as-
pects of protein aggregation cardiomyopathy are avail-
able and have been exploited to implicate cardiac-specific
expression of mouse R120G (mR120G) CryAB in myofi-
brillar impairment and cardiac hypertrophy mimicking
DRM (Wang et al., 2001). Here we report on transgenic
mice harboring human R120GCryAB (hR120GCryAB Tg)
that fully recapitulate the morphological, functional, and
molecular features of human CryAB cardiomyopathy.
Several Hsps were induced by hR120GCryAB Tg but the
most pronounced was Hsp25 expression, the redox-
dependent chaperone. Induction of Hsp25 preceded the
onset of heart failure.
We hypothesized that molecular interactions bet-
ween misfolded protein expression and the glutathione-
dependent redox state play a key role in the pathogenesis
of hR120GCryAB cardiomyopathy. Our data have revealed
profound increases in reduced GSH concentrations and
the ratio of GSH/GSSG, likely by the increased conversion
of oxidized GSSG to reduced GSH. The enzymatic acti-
vities of glucose-6-phosphate dehydrogenase (G6PD),
glutathione reductase, glutathione peroxidase, and cata-
lase were all significantly increased by dose-dependent
hR120GCryAB Tg expression. Moreover, the biochem-
ical and molecular consequences of hR120GCryAB Tg
expression were prevented when G6PD-deficient (20%
normal activity) animals were crossed with hR120GCryAB
Tg cardiomyopathic mice, providing direct evidence to
support ‘reductive stress’ as a causative mechanism in
hR120GCryAB induced cardiomyopathy.
RESULTS
Transgene Overexpression of WT and Human
R120GCryAB in Mice
To create a small animal model of missense human
R120GCryAB expression (hR120GCryAB), we generated
transgenic mice using the mouse a-myosin heavy chain
(aMHC) promoter driving the expression of either the
human cDNA CryAB wild-type (hCryAB Tg) gene or the
R120G mutated form in a tissue-specific manner. Two
transgenic lines were established for each construct; lines428 Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc.3241 and 3244 for aMHC hCryAB Tg and lines 7302 and
7313 for aMHC hR120GCryAB Tg. Transgene transmis-
sion to the off-spring was analyzed by Southern blot and
PCR. CryAB protein in both supernatant and pellet frac-
tions of heart homogenates from 6 month old mice was
probed by Western blot for nontransgenic controls
(NTg), hCryAB Tg, and hR120GCryAB Tg animals (Fig-
ure 1A). Total CryAB protein, reflecting endogenous and
transgene expression, was increased 1.5 fold greater in
line 3241 hCryAB Tg, 2 fold in line 7313 hR120GCryAB
Tg and 6 fold in line 7302 hR120GCryAB Tg (Figures 1A
and 1B). These two transgenic lines, with mild and moder-
ate hR120G CryAB overexpression, were designated
hR120GCryAB Low Tg and hR120GCryAB High Tg, re-
spectively. Whereas hCryAB Tg protein remained entirely
soluble, hR120GCryAB Tg protein was found in both sol-
uble and insoluble fractions, indicating that mutant protein
expression recapitulates the protein aggregation disorder,
a proposed model for desmin-related myopathies (Vicart




Moderate overexpression of hR120GCryAB Tg protein in
the mouse heart induced cardiac hypertrophy, progres-
sive heart failure and premature death (Figures 1C–1F).
Magnetic resonance imaging (MRI) was used to confirm
cardiac hypertrophy and severe ventricular remodeling
with dilatation in end-stage hR120GCryAB Tg cardiomyo-
pathic mice (Figure S1 and Table S1 in the Supplemental
Data available with this article online). At 6 months, mor-
phological analyses consistently revealed gross four-
chamber enlargement, biatrial thrombosis and cardiac
hypertrophy in hR120GCryAB High Tg mice (Figure 1D
and Table S2). Large aggregates were present in myocar-
dial sections of hR120GCryAB High Tg but were not pres-
ent in either hCryAB Tg or hR120GCryAB Low Tg mice
(compare Figures 1E and S2A).
Beyond 6 months, the rate of disease progression ac-
celerated for hR120GCryAB High Tg animals character-
ized by increased lethargy and systemic edema from fluid
retention (Figure 1C), reaching 100% mortality at 66 weeks
(Figure 1F). Consistent with this accelerated attrition, the
viability of cardiomyocytes isolated from hR120GCryAB
High Tg was significantly decreased compared with either
hR120GCryAB Low Tg or NTg control hearts (Figure S2B).
A 20% mortality from sudden death after 80 weeks was
noted in hR120GCryAB Low Tg mice (Figure 1F). There
were no effects on mortality in either hCryAB Tg mice or
nontransgenic (NTg) littermates over 80 weeks (Figure 1F).
Neither abnormal baseline cardiac function nor overt signs
of heart failure were present in hR120GCryAB Low Tg mice
(Table S2), but cardiac contractile reserve in response to
dobutamine challenge was decreased compared with
NTg controls (Figure S2C).
RNA dot blots showed that markers of cardiac hypertro-
phy and congestive heart failure, such as atrial natriuretic
Figure 1. Cardiac-Specific Overexpression of hR120GCryAB Causes Protein Aggregation Cardiomyopathy in Transgenic Mice
(A) Representative Westerns of either the soluble (supernatant) or insoluble (pellet) fractions isolated from hearts of 6 month old nontransgenic (NTg),
human aB-crystallin (hCryAB Tg), hR120GCryAB Low Tg, and hR120GCryAB High Tg animals. Each lane represents an individual animal.
(B) Human R120GCryAB overexpression causes translocation of CryAB into the insoluble fraction in a dose-dependent manner. Fold changes are
expressed in arbitrary units relative to NTg (*p < 0.001).
(C) Congestive heart failure exhibited by systemic edema in hR120GCryAB High Tg mice at 10 months.
(D) Human R120GCryAB overexpression causes ventricular enlargement along with biatrial thrombosis consistent with heart failure at 6 months.
(E) Indirect immunofluorescence analysis of heart sections stained with anti-CryAB detected by FITC conjugated secondary antibodies shows large
protein aggregates (green) in cardiomyocytes of hR120GCryAB High Tg hearts (inset/arrow).
(F) Survival Curve. Transgenic hR120GCryAB High mice developed congestive heart failure and died between 24 and 65 weeks. Most hR120GCryAB
Low Tg mice (80%) were alive after 80 weeks. No differences in mortality were observed between hCryAB Tg and NTg littermates. All results
represent mean ± SD of 3–6 animals/group.factor (ANF) and brain natriuretic factor (BNF), were all
increased at 3 and 6 months, whereas phospholamban
(PLN) expression, a major regulator of cardiac contractility
and relaxation, was decreased with the onset of heart
failure in 6-month old hR120GCryAB High Tg myopathic
hearts (Figure S3).Major Hsps, Especially Hsp25, Are Induced
by hR120GCryAB Expression
Activation of stress response pathways exemplified by
members of the multigene families of heat shock proteins
(Hsps) has been documented in human heart failure
(Knowlton et al., 1998). To characterize the effects ofCell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 429
Figure 2. Mutant hR120GCryAB Induces the HSP Stress Response Pathway
(A and B) Representative Western blot experiments of (A) supernatants or (B) insoluble fractions (pellets) from heart extracts of 6 month old NTg,
hCryAB Tg, hR120GCryAB Low Tg and hR120GCryAB High Tg mice, immunoblotted with anti-Hsp25, -Hsp70, and -Hsp90 antibodies. Each lane
represents an individual animal (3 animals/group).
(C and D) Densitometry values are represented as relative intensities in mean arbitrary units calculated from the Western blots shown in Figures 2A
and 2B, respectively (*p < 0.05, **p < 0.01, yp < 0.001 versus NTg).
(E and F) Northern blots show that Hsp25 transcripts are significantly increased in hR120GCryAB High Tg hearts at 3 and 6 month old animals (*p <
0.05 versus 3 month NTg). All results represent mean ± SD of 3–6 animals/group.hR120GCryAB overexpression on Hsp expression in
myopathic hearts, representative members of the major
Hsp families were assessed by Western blot analysis in
6 month old mice, an arbitrary transition point associated
with progression of heart failure and increased mortality.
Levels of Hsp90, an ATP-dependent chaperone that
forms multiprotein complexes, were 2 fold higher for
hR120GCryAB High Tg hearts compared to NTg, hCryAB
Tg, or hR120GCryAB Low Tg hearts in both soluble and in-
soluble fractions (Figures 2A–2D). Similarly, Hsp70 levels
were increased by 2 fold in the soluble fraction of cardiac430 Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc.homogenates of hR120GCryAB High Tg compared with
NTg expression. Hsp25 protein, a non-ATP dependent
chaperone that forms multimeric oligomers, was modestly
increased in the supernatant fraction, but this chaper-
one was > 25 fold higher in the insoluble fraction of
hR120GCryAB High Tg hearts compared to NTg, hCryAB
Tg, or hR120GCryAB Low Tg hearts (Figures 2B and 2D).
Of note, levels of Hsp25 were indistinguishable among
these four experimental groups at 2 months (Figure S4)
but mRNA levels of Hsp25 were increased by 2.5 fold in
hR120GCryAB High Tg compared with hCryAB Tg at
Figure 3. Enzyme Activity and Expression of Glutathione Peroxidase-1 (GPx-1) and Catalase at 6 Months
(A and B) Mutant hR120GCryAB High Tg overexpression enhances the activities of GPx-1 and catalase (*p% 0.05) in 6 month old hearts.
(C and D) At 6 months, protein expression for GPx-1 is unchanged but catalase was increased in hR120GCryAB High Tg compared with NTg, hCryAB
Tg and hR120GCryAB Low Tg animals. Each lane represents an individual animal.
(E) Densitometry of Western blots presented in Figure 3C reveals that catalase level was increased by 5 fold in hR120GCryAB High Tg compared
with the other groups (**p < 0.02).
(F) Northern blot analysis using radio-labeled cDNA probes against GPx-3 and catalase (Cat). Total RNA was harvested from NTg, hCryAB Tg and
hR120GCryAB High Tg at either 3 or 6 months.
(G and H) Densitometry analysis of Northern blots of Figure 3F expressed in arbitrary units shows 2-3 fold increases for GPx-3 (G) and 5-fold
increase for catalase (H), in both 3 and 6 month old hR120GCryAB High Tg hearts (*p < 0.05 versus 3 month NTg). Each lane represents an individual
animal (3 animals/group). All results represent mean ± SD of 3-6 animals/group.3 and 6 months (Figures 2E and 2F), indicating
hR120GCryAB Tg protein expression causes upregulation
of stress-inducible Hsps in vivo. These data indicate that
hR120GCryAB Tg protein expression causes differential
upregulation of stress-inducible Hsps in vivo with a major
effect on Hsp25 expression.
R120GCryAB Expression Causes Early
Enhancement of Antioxidative Pathways
We next determined if increased synthesis of major Hsps
might be accompanied by the induction of antioxidant
pathways, which detoxify ROS in vivo. Both catalase
and the glutathione peroxidase catalyze the dispositionof H2O2 into H2O and O2. The enzymatic activity of gluta-
thione peroxidase, which catalyzes the elimination of per-
oxides, was 70% higher in hR120GCryAB High Tg hearts
compared with NTg controls at 6 months (Figure 3A), but
cytosolic GPx-1 protein assessed by immunoblot analysis
was similar among all groups (Figures 3C and 3D). Moder-
ate increase in GPx activity (Figure 3A) without a commen-
surate increase in GPx protein expression may reflect the
translational limitations of available selenium, which is not
standardized in chows, and/or of the translational cofac-
tors required for selenoprotein synthesis (Handy et al.,
2006). Similarly, the activity of catalase in hR120GCryAB
High Tg was 50% and 100% higher than either NTg orCell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 431
Table 1. Concentrations of Reduced (GSH) and Oxidized (GSSG) Glutathione in Heart Tissue Homogenates
at 6 Months
Parameter/Groups Nontransgenic hCryAB Tg hR120GCryAB Low Tg hR120GCryAB High Tg
Total GSH (nmol/mg
protein) (N = 6)
811.19 ± 125.87 937.06 ± 97.90 1006.01 ± 58.74 1573.02 ± 33.57y
GSSG (nmol/mg
protein) (N = 6)
18.20 ± 1.6** 24.51 ± 1.7 24.01 ± 0.8 24.51 ± 0.9
GSH/GSSG 44.39 ± 3.02 38.17 ± 1.35 41.88 ± 1.05 64.54 ± 3.50*
Values are expressed as mean ± SD calculated for six animals in each individual experiment. yp = 0.001 hR120GCryAB High Tg
compared to other groups. **p < 0.025 NTg compared to other groups. *p < 0.05 hR120GCryAB High Tg compared to other groups.hCryAB Tg hearts, respectively (Figure 3B) and protein
abundance of catalase in hR120GCryAB High Tg was 5-
and >2- fold greater than either NTg or hCryAB Tg hearts,
respectively (Figures 3C and 3E).
At both 3 and 6 months, we observed that mRNA levels
of glutathione peroxidase (GPx-3) and catalase were 2.5
and 5 fold higher in hR120GCryAB High Tg hearts com-
pared with NTg controls, respectively (Figures 3F–3H).
As upregulation of HSP stress pathway parallel the activa-
tion of antioxidative enzymes at 3 and 6 months (Figures
2E and 2F and 3F–3H), the results suggest that key cyto-
protective pathways are recruited as early compensatory
events in response to mutant hR120GCryAB expression,
in part, to mitigate increased oxidative stress.
R120GCryAB Tg Expression Causes Oxido-Redox
Shift Toward Reductive Stress
We first determined if myopathic hearts might respond
with increased GSH levels and alterations in redox bal-
ance as Hsp25 has been implicated in GSH metabolism
(Baek et al., 2000; Mehlen et al., 1996). The concentrations
of reduced glutathione (GSH) and oxidized glutathione
(GSSG) in heart homogenates of 6 month old experimental
groups are shown in Table 1. The relative amounts of total
GSH revealed the following rank order: hR120GCryAB
High Tg > hR120GCryAB Low Tg > hCryAB Tg > Non-
Tg. The total GSH content of hR120GCryAB High Tg
was significantly increased by 2 fold compared with
NTg controls (Table 1). The amount of GSSG in all Tg
groups was 25% higher than NTg controls, but only the
higher GSH:GSSG ratio in hR120GCryAB High Tg hearts
reached statistical significance compared to NTg controls.
We next assessed the susceptibility of intracellular
lipids to peroxidation using malondialdehyde (MDA) and
proteins to undergo oxidative modifications by anti-
dinitrophenylhydrazine (DNPH) immunostaining as surro-
gate biomarkers (Figures S5A-C). At 6 months, both MDA
levels and anti-DNPH immunoreactive proteins were sig-
nificantly and unexpectedly lower in hR120GCryAB High
Tg hearts compared with the NTg control (Figures S5A-
B, respectively). Taken together, our results suggest that
the effects of high level of hR120GCryAB expression
dramatically increases reducing power, exemplified by
the higher GSH concentrations and GSH:GSSG ratio.432 Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc.R120GCryAB Overexpression Activates the GSH
Biosynthesis-Recycling Pathway
Our findings of increased expression and activities of
key antioxidative enzymes such as catalase and glu-
tathione peroxidase, and GSH elevation (Table 1), in
hR120GCryAB High Tg heart homogenates warranted a
systematic assessment of each enzymatic step that cat-
alyzes either the recycling of GSH and/or de novo synthe-
sis pathways (Figure 4A). Reduced glutathione (GSH) is
generated from oxidized GSSG by the oxidation of nicotin-
amide adenine-dinucleotide phosphate, NADPH, a prod-
uct of the glucose-6-phosphate dehydrogenase (G6PD)
reaction. G6PD is the rate-limiting enzyme of the pentose
phosphate ‘‘shunt’’ pathway of anaerobic glycolysis (Pre-
ville et al., 1999). The G6PD enzyme activity in heart ho-
mogenates for hR120GCryAB High Tg was 2 fold greater
than NTg, hCryAB Tg, or hR120GCryAB Low Tg at 6
months (Figure 4B). Myocardial abundance of G6PD pro-
tein, however, was 4 fold higher in hR120GCryAB High
Tg than NTg, hCryAB Tg, or hR120GCryAB Low Tg at
6 months (Figures 4D and 4E).
We next tested glutathione reductase (GSH-R) activity,
which uses NADPH as the principal source of reducing
equivalents for recycling oxidized GSSG to reduced
GSH. Both enzymatic activity and protein content of
GSH-R were significantly increased in hR120GCryAB
High Tg hearts compared to NTg, hCryAB Tg, and
hR120GCryAB Low Tg hearts at 6 months, (Figures 4C,
4D, and 4F). The enzymatic activity and protein abun-
dance of gamma-glutamyl cysteine synthetase (g-GCS),
the rate-limiting enzyme for biosynthesis under feedback
inhibition by GSH, were indistinguishable among all exper-
imental groups examined (data not shown), indicating that
increased GSH recycling pathway, and not de novo bio-
synthesis, is the predominant mechanism responsible
for elevated GSH levels in response to increased
hR120GCryAB expression.
Cardiac-Specific hR120GCryAB Promotes
Interactions with Hsp25 and G6PD
We hypothesize that vulnerability to hR120GCryAB ex-
pression arises from a toxic gain-of-function mechanism
caused by other client protein interactions with either
Hsp25 and/or G6PD. To determine if hR120GCryAB
protein expression has direct effects on molecular
Figure 4. R120GCryAB Overexpression
Enhances Antioxidative Enzymatic and
GSH Recycling Pathways
(A) The schematic diagram illustrates the
effects of hR120GCryAB expression on upre-
gulation of Hsp25 and G6PD, the first and
rate-limiting enzyme of the anaerobic pentose
phosphate pathway and major source of
reducing equivalents in the form of NADPH.
Reduced glutathione (GSH) is generated by
increased activity of glutathione reductase
from recycling and not from de novo synthesis.
Catalase and glutathione peroxidase (which
consumes GSH) catalyze the conversion of
reactive oxygen species such as hydrogen
peroxide to H2O.
(B) Human hR120GCryAB causes modest in-
crease in G6PD enzyme activity in 6 month
old hR120GCryAB High Tg expressors com-
pared with the control groups (*p < 0.05).
(C) Glutathione reductase, which catalyzes the
recycling of GSSG to GSH, exhibits increased
activity and expression in heart homogenates
with hR120GCryAB High Tg expression at
6 months (*p < 0.05 versus NTg).
(D) Representative Western blot analysis of
G6PD, GSH-R and g-GCS protein expression
in 6 month old hR120GCryAB High Tg animals.
(E and F) Densitometry analysis of the protein
bands expressed in arbitrary units shows
4 fold increase of G6PD (n = 6) and 40% in-
crease of GSH-R in the transgenic hearts with
hR120GCryAB High expression compared to
NTg, respectively (*p < 0.05). All results repre-
sent mean ± SD ofR 6 animals/group.interactions involving the GSH biosynthetic pathway,
we performed reciprocal coimmunoprecipitations and im-
munoblot analysis in heart homogenates. The interactions
between G6PD and either CryAB or Hsp25 were found in
heart extracts from hCryAB Tg, hR120GCryAB Low Tg
and hR120GCryAB High Tg but were negligible for NTg
(Figure 5A). More robust molecular interactions were
seen for both CryAB and Hsp25 for G6PD, which might
represent chaperone-dependent properties in vivo (Fig-
ures 5A and 5B).
Using confocal microscopy, the patterns of distribution
and localization for Hsp25 and CryAB were similar within
the core of large protein aggregates (Figure 5C). In
contrast, G6PD was more diffusively distributed along
the myocardial striations and occasionally but not exclu-
sively surrounding protein aggregates containing both
CryAB and Hsp25 proteins (Figure 5C). These findings
provide evidence that molecular interactions between
mutant CryAB and Hsp25 or G6PD might promote the
pathogenesis of hR120GCryAB expression leading to
cardiomyopathy.G6PD Deficiency Prevents Cardiac Hypertrophy
and Protein Aggregation in hR120GCryAB
High Tg Cardiomyopathic Mice
If causal mechanisms are linked to marked upregulation
of G6PD, then maneuvers that either inhibit and/or down-
regulate this pathway should reverse redox imbalance
triggering hR120GCryAB Tg cardiomyopathy. To test
this hypothesis, male hemizygous G6PD mutant mice
(G6PDmut, C3H background) were crossed with hetero-
zygote hR120GCryAB High Tg animals to generate
hR120GCryAB High Tg/G6PDmut mice. In the G6PDmut
homogenates, the X-linked gene encoding G6PD main-
tains 20% of the normal enzymatic activity under the
control of the native promoter (Figure 6A).
G6PD enzyme activity and expression in hR120GCryAB
High Tg were 2.5 - 3.0 fold greater than in either NTg or
hR120GCryAB High Tg/G6PDmut (Figures 6A–6D). In con-
trast, the modulation of G6PD enzyme activity and expres-
sion in hR120GCryAB High Tg/ G6PDmut hearts was not
different from NTg. Compared with NTg animals, GSH
content was modestly increased in hR120GCryAB HighCell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 433
Figure 5. R120GCryAB Overexpression Promotes Colocalization and Interactions Between G6PD and Hsp25 in Protein
Aggregates
(A) Representative Westerns of supernatant fractions from heart homogenate after coimmunoprecipitation were performed and probed with anti-
G6PD, anti-CryAB and anti-Hsp25 antibodies. A vertical bar (j) indicates cropped lanes made in the original gel image to remove irrelevant spaces.
(B) Densitometry analysis of immunoblots indicates significant interactions among CryAB, Hsp25 and G6PD in the hR120GCryAB High Tg group.
G6PD/CryAB (panels A and B-a); CryAB/G6PD (panels A and B-b); G6PD/Hsp25 (panels A and B-c); and Hsp25/G6PD (panels A and B-d).
(*p < 0.05, **p < 0.01 compared with NTg control).
(C) Protein aggregates in hR120GCryAB High Tg mice contain moderate levels of both CryAB (b, shown in green) and Hsp25 at 6 months (d, red).
G6PD is also expressed more diffusely (f, blue) but appears to be slightly concentrated in or around the aggregates (h, three images merged). Inset
arrow (panel h) is a higher magnification of a representative myocardial section contained in the squares (panels b, d, f, and h). No aggregates are seen
in transgenic mice expressing the wild-type version of human CryAB (panels a, c, e, and g). All results represent mean ± SD of 3–6 animals/group.Tg (30%) and hR120GCryAB High Tg/G6PDmut (14%)
(data not shown).
Moreover, the anticipated increases in total CryAB and
Hsp25 protein levels were similar between hR120GCryAB
High Tg and hR120GCryAB High Tg/G6PDmut hearts, indi-
cating myocardial total CryAB or Hsp25 expression
induced by the hR120GCryAB High transgene was unal-
tered by G6PD deficiency in vivo. (Densitometry measure-
ments are not shown for CryAB owing to technical inabil-
ity to distinguish individual lanes showing equivalent
CryAB overexpression in hR120GCryAB High Tg and
hR120GCryAB High Tg/G6PDmut hearts.)434 Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc.Cardiac hypertrophy is a constant finding of
hR120GCryAB High Tg cardiomyopathy and a major risk
for heart failure in experimental models and humans
alike. Indeed, heart weight/body weight ratio in 6 month
old hR120GCryAB High Tg was 33% greater than
hR120GCryAB High Tg/G6PDmut (6.15 ± 1.06 versus
4.63 ± 0.27, p < 0.05), the latter being similar to NTg
(4.63 ± 0.27 versus 4.50 ± 0.19, NS) as shown in
Figure 6B. Such profound effects in preventing the hyper-
trophic response in hR120GCryAB High Tg/G6PDmut
hearts were confirmed at the molecular level using several
biomarkers for cardiac hypertrophy (Figure S6). Lastly,
Figure 6. G6PD Deficiency Prevents Cardiac Hypertrophy and Protein Aggregation in hR120GCryAB High Mice In Vivo
(A) G6PD activity in heart homogenates of hR12GCryAB High Tg/G6PDmut is similar to NTg and significantly lower than hR12GCryAB High Tg at
6 months (p < 0.01).
(B) Cardiac hypertrophy (assessed by heart weight/body weight ratio) caused by hR120GCryAB Tg overexpression was completely prevented by
G6PD deficiency in R12GCryAB High Tg/G6PDmut hearts. HW, heart weight; BW, body weight.
(C and D) Protein abundance of total CryAB, Hsp25, G6PD, and MnSOD in hR120GCryAB High Tg and hR120GCryAB High Tg/G6PDmut hearts. Each
lane in panel C represents an individual animal per experimental group (3 animals/group). (*p < 0.05, y p < 0.015, **p < 0.001 when compared with
NTg). Lane 13 is blank in G6PD and Hsp25 panels. All results represent mean ± SD of 3–10 animals/group.
(E) G6PD deficiency prevents protein aggregation in hR120GCryAB High Tg expression crossed into G6PDmut animals. Arrows in panel (a) point to
examples of the large protein aggregates (green, CryAB; red, Hsp25; and blue, G6PD), which are not found in the transgenic hR120GCryAB High
Tg/G6PDmut mice (b).G6PDmut intercross with hR120GCryAB High Tg com-
pletely prevents protein aggregation (Figure 6E), consistent
with abrogating the manifestations of cardiomyopathy.Of note, the decreased survival of cardiomyocytes from 6
month old hR120GCryAB High Tg, which was reduced by
30% compared with age-matched hR120GCryAB LowCell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 435
Tg or NTg animals (Figure S2B), was fully reversed by
G6PD deficiency (data not shown). The reversal in G6PD
enzyme activity, prevention of protein aggregation, and ab-
rogation of cardiac hypertrophy in hR120GCryAB High Tg/
G6PDmut hearts demonstrate for the first time that G6PD
plays a key role in production of reductive stress of the
disease-causing hR120GCryAB mutation in mammals.
DISCUSSION
Our findings in hR120GCryAB mice mimic the clinical
manifestations, phenotypic heterogeneity and late-onset
of clinical signs and symptoms observed in DRM patients
(Dalakas et al., 2000; Goldfarb et al., 1998). Multiple lines
of evidence suggest that increased reducing power is
causally linked to hR120GCryAB cardiomyopathy. Reduc-
tive stress has been demonstrated in lower eukaryotes
(Simons et al., 1995; Trotter and Grant, 2002), but uncom-
monly in mammals and/or disease states (Chance et al.,
1979). In hR120GCryAB High Tg mice, reductive stress
appears to decrease myocyte viability and to increase
cardiac remodeling leading to cardiac dysfunction and
heart failure. Adverse effects of reductive stress are not
restricted to cardiac myocytes. In WEH17.2 lymphoma
cells, G6PD-overexpression increased reducing equiva-
lents in the form of NADPH, decreased ATP synthesis by
mitochondria, and increased their sensitivity to reactive
oxygen species and apoptosis (Tome et al., 2006). In ad-
dition, overproduction of reducing equivalents (i.e., GSH)
by increases in G6PD activity likely imparts pleiotropic
effects on gene expression, mitochondrial dysfunction
(Maloyan et al., 2005), and protein quality control(Bukau
et al., 2006) in cardiomyopathic mice. Although the molec-
ular basis for lethal arrhythmias is presently unknown,
hR120GCryAB cardiomyopathic mice represent an excel-
lent model to explore the cellular mechanisms potentially
involving reductive stress on redox-sensitive ion channels
in arrhythymogenesis.
Increased G6PD Activity Is Necessary and Sufficient
for R120GCryAB Cardiomyopathy
Several potential transcriptional and posttranscriptional
mechanisms might account for reductive stress including
upregulation of G6PD protein expression and enzymatic
activity. We found that mRNA levels of G6PD are in-
creased by 3 months in hR120GcRyAB High Tg animals
(unpublished results), suggesting early activation of
G6PD expression is designed to limit hR120GCryAB-
induced oxido-reductive stress (Kletzien et al., 1994).
Marked increases in G6PD protein content, however, cor-
related with only modest increases in G6PD activity in 6
month old hR120GCryAB mice (Figures 4B, 4D, and 4E),
suggesting post-translational mechanisms are involved
in regulating enzyme activity. In studies involving inter-
crosses between hR120GCryAB High Tg and G6PDmut
allele animals, the effects on GSH overproduction were
not as robust as the effects of G6PD activity, but variations
in genetic background among individual animals (resulting436 Cell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc.from the C57BL6/C3H intercrossing) might explain these
differences. G6PDmut has reduced, not absent, G6PD
activity under the control of its native promoter, allowing
for regulation of expression and an increase in activity
(although significantly blunted) in intercross mice.
The role of G6PD in modulating oxidant stress and oxi-
dant signaling has been established in cardiomyocytes
and in endothelial cells (Leopold et al., 2001, 2007). In ex-
perimental systems and in human heart failure, increased
protein content and enzymatic activity of G6PD have cor-
related with elevated NADPH, a primary source of reduc-
ing equivalents. NADPH is used by glutathione reductase,
for example, to increase the GSH pool, which serves to
neutralize the effects of superoxide production (Gupte
et al., 2006; Sam et al., 2005). Future studies will deter-
mine if chaperone-dependent (i.e., Hsp25 or CryAB) inter-
actions contribute to the dysregulation of G6PD activity
in DRM (Clemen et al., 2005), and if heat shock transcrip-
tion factor 1, the major stress-inducible transcriptional ac-
tivator (Morimoto, 1998), governs R120GCryAB-induced
upregulation of Hsp25 expression. Since chaperone
functions of CryAB have been shown to restore the enzy-
matic activity of denatured G6PD in vitro (Kumar et al.,
2005), it is possible that increased CryAB, a bona fide
heat shock protein (Klemenz et al., 1991), might paradox-
ically increase G6PD activity. Our findings open new lines
of investigations to determine if mutant R120GCryAB
pathogenesis involves native complexes or novel interac-
tions with presently unrecognized targets.
A Toxic Gain-of-Function Mechanism
for R120GCryAB Cardiomyopathy
Our rescue experiments (Figure 6) strongly support the
causal mechanism of G6PD activity and not levels of
hR120GCryAB per se in protein aggregation. Protein
aggregates, congophilic amyloid materials and oligomer-
ization are the morphological hallmarks of DRM (Dalakas
et al., 2000; Selcen et al., 2004; Vicart et al., 1998), but
Sanbe and coworkers have recently implicated oligomer
formation, not protein aggresomes, in reversible myocar-
dial dysfunction in mR120GCryAB transgenic mice
(Sanbe et al., 2004). Insights about the molecular mecha-
nisms of amyloid formation remain poorly defined, and the
toxicity arising from aggresomes in the pathogenesis of
degenerative diseases are controversial (Johnston et al.,
1998). Previous studies have reported increased G6PD
activity mimicking reductive stress in the distinct cortical
regions of affected individuals with Alzheimer’s disease
(Russell et al., 1999) but such relationships to the mecha-
nisms of neurofibrillary formation and aggregation have
not been established. Because the defective chaperone
R120GCryAB is prone to misfolding and self-aggregation,
a loss-of-function mutation has been hypothesized for
DRM characterized by protein aggregates containing
desmin and other misfolded proteins (Bova et al., 1999).
A plausible alternative hypothesis is that toxic gain-of-
function mutations lead to excess reducing equivalents.
This might occur at sites of macromolecular complex
formation involving cytosolic components (e.g., Hsp25),
intermediate filament proteins (e.g., desmin), a mutant
chaperone and G6PD, providing a potential causative
mechanism for the initiation of pathogenic oligomerization
and protein aggregation. Long-term studies are needed to
determine if cardiac remodeling and ventricular dysfunc-
tion are prevented, and if survival is fully restored in
hR120GCryAB High Tg/G6PDmut mice.
Our findings identify reductive stress as a key cellular
metabolic derangement in the molecular pathogenesis
of hR120GCryAB-induced protein aggregation cardiomy-
opathy. Increased G6PD expression reflects a maladap-
tive mechanism in hR120GCryAB cardiomyopathy, sug-
gesting that targeted downregulation, by pharmacologic
or other maneuvers, might modify the phenotype and
the natural history of this inherited disorder in humans.
The induction of reductive stress might also represent
a common mechanism in the pathogenesis of cardiac
and other degenerative diseases.
EXPERIMENTAL PROCEDURES
Transgenic Constructs, Mouse Lines, and Care
The full-length human aB-crystallin (CryAB) was kindly provided by
Dr. Goldman (Columbia University). The missense mutation, R120G,
was created from the human CryAB cDNA by PCR-based mutagene-
sis (Quick Change Site directed mutagenesis kit, Stratagene, LaJolla)
and confirmed by sequencing. Subsequently, the cDNAs were placed
under the control of alpha-myosin heavy chain (aMHC) promoter (gift
from Dr. Jeffrey Robbins, University of Cincinnati, OH). Transgenic
mice were generated by pronuclear injection according to standard
procedure. Founders were identified by PCR and Southern blot analy-
sis and crossed with wild-type C57/BL6 mice to establish the trans-
genic lines. Hemizygous mice for the X-linked gene encoding G6PD
with 20% of the normal enzymatic activity were obtained from Drs.
Jane Leopold and Joseph Loscalzo at Harvard Medical School (Leo-
pold et al., 2003). Standard mouse breeding was used to generate
compound R120G High/G6PDmut heterozygotes. Mice were fed with
standard diet and had access to water and food ad libidum; they
were housed under controlled environment with 23 ± 2C and 12 hr
light/dark cycles. All experimental protocols followed the US Animal
Welfare Acts and NIH guidelines and were approved by the University
of Utah Animal Care and Use Committee.
Antibodies and Reagents
The following antibodies and reagents were used: an anti-CryAB poly-
clonal antibody, which recognizes both the mouse and human proteins,
was raised against residues 164-175 of human CryAB. Rabbit
anti-Hsp25, anti-Hsp70, anti-Hsp90 (StressGen, Victoria, BC, Canada)
and rabbit anti-G6PD (Novus Bio.), anti-catalase, anti-glutathione per-
oxidase, anti-glutathione reductase (AbCam), gamma-GCS/glutamate
cysteine ligase-Ab1 (Labvision, Neomarkers, CA) and Anti-DNP (Sigma
Chemicals Co, St. Louis, MO) antibodies were purchased from com-
mercial vendors. Acrylamide/bis-acrylamide, ammonium persulfate,
protein assay reagent, protein standard markers (Bio-Rad, Richmond,
CA) and enzymatic assay kits for reduced and oxidized glutathione,
catalase, glutathione peroxidase, glutathione reductase were obtained
from Bioxitech (Oxis Research). RNeasy, DNA purification kits
(QIAGEN, Valenica, CA) and Northern Max kit (Ambion, Austin, TX),
[a-32P]dATP (Amersham) were obtained commercially.
Protein Isolation, Western Blot, and Immunoprecipitation
See Supplemental Data.Glutathione Measurements
Hearts were dissected, atria and large vessels trimmed and rinsed
briefly in PBS. Hearts were weighed, flash frozen, pulverized and
homogenized in 5% sulphosalisilic acid (SSA) and centrifuged,
10,000 x g, at 4C for 10 min. Supernatant was removed and used
for GSH assay. GSSG content was measured by using 100 ml fraction
of the supernatant adding 2 ml of 2-vinylpyridine and 10ml of 50%
triethanolamine, which was kept at room temperature for 1 hr. Total
glutathione and oxidized glutathione (samples derivatized with 2-vinyl
pyridine) were measured by a standard recycling assay based on the
reduction of 5,5-dithiobis-2-nitrobenzoic acid in the presence of gluta-
thione reductase and NADPH (Griffith, 1980).
Antioxidant Enzyme Activity Assays
See Supplemental Data.
Glucose-6-Phosphate Dehydrogenase Activity
Cytoplasmic extracts were prepared as described above and were
used to assess the G6PD activity (Hochman et al., 1982). Protein
aliquots were prepared in 90 mM triethanolamine, (pH 7.6), 10 mM
MgCl2, 198 mM G-6-phosphogluconate and 100 mM NADP
+. Similar
reaction mixtures with 198 mM of glucose-6-phosphate were also pre-
pared to measure the activity of 6-phospho gluconate dehydrogenase.
The solutions were mixed and absorbance was read at 340 nm every
2 min for 20 min. The specific activity of glucose-6-phosphate dehy-
drogenase was determined by calculating the difference between
the readings from the two reactions.
Extraction of RNA, Northern and Dot Blot Analyses
See Supplemental Data.
Morphological Analysis and Immunohistofluorescence Assays
The right atrium of anesthetized mice was cut and the hearts were per-
fused through the apex with saline (0.9% NaCl) for 5 min to remove all
blood. Hearts were then fixed for 10-12 min by perfusion of 0.1% para-
formaldehyde in cardioplegic buffer (50 mM KCl and 5% dextrose),
removed from the chest cavity, cut in half coronally, and cryoprotected
by successive incubations in 10% sucrose in PBS/0.05% NaN3 (at
least 3 hr) and 30% sucrose in PBS/0.05% NaN3 (at least 6 hr). Hearts
were frozen in OCT and sectioned at 5 mm using a cryostat. Dried cry-
osections were washed in PBS and blocked for 30 min at room tem-
perature in blocking solution (1% BSA, 0.1% fish skin gelatin [Sigma
G7765], 0.1% Tween 20, and 0.05% NaN3 in PBS). For detecting
CryAB alone, the sections were incubated at room temperature for
45 min with rabbit anti-CryAB antibody (1:100 in PBS; made at Univer-
sity of the Texas Southwestern Medical Center at Dallas, TX), washed
three times with PBS for 5 min each wash, and then incubated at room
temperature for 45 min with donkey anti-rabbit Alexa 488 (1:100; Mo-
lecular probes A21206) and TO-PRO-3 642/661 (1:100 of 1 mM stock
solution dissolved in DMSO; Molecular Probes T3605). The sections
were washed three times as described above and stained with phalloi-
din-Alexa 568 (1/20 dilution in PBS of a stock solution containing
0.2 units/ml dissolved in methanol; Molecular Probes A12380) at
room temperature for 20 min, washed three times as described above,
and then mounted with Vectashield Hard Set mounting medium (Vec-
tor Laboratories). Nail polish was used to seal the edges of the cover-
slip once the mounting medium dried. The sections were observed and
photographed using a laser-scanning Olympus IX81 confocal micro-
scope equipped with Argon and HeNe excitation lasers at 488 nm,
543 nm, and 633 nm.
When performing immunohistofluorescence assays to detect
CryAB, Hsp25, and G6PD simultaneously, the following modified pro-
cedure was followed. These modifications were required to enable the
simultaneous use of two different rabbit polyclonal antibodies and
a mouse monoclonal antibody on mouse tissue sections. The rabbit
anti-G6PD antibody (1:50 in PBS; Novus NB100-236) was first incu-
bated with the tissue sections as described above and excessCell 130, 427–439, August 10, 2007 ª2007 Elsevier Inc. 437
unbound antibody was removed by three washes in PBS for 5 min
each. Bound rabbit anti-G6PD was then converted to goat antibody
by incubating the tissues with goat anti-rabbit Fab (1:20 dilution in
PBS; Jackson Immuno-Research 111-007-003) at room temperature
for 45 min. The tissues were washed three times with PBS as de-
scribed above and then incubated 45 min at room temperature with
donkey anti-goat Alexa 488 (1:100 in PBS; Molecular Probes
A11055) to detect G6PD and donkey anti-mouse Fab antibody (1:20
in PBS; Jackson Immuno-Research 715-007-003) to block endoge-
nous mouse immunoglobulins in preparation for the anti-Hsp25 anti-
body. A control slide was incubated with goat anti-rabbit Alexa 633
(1:100 in PBS; Molecular Probes A21070) to ensure complete conver-
sion of the rabbit antibody to an immunoreactive goat antibody. The
tissue sections were washed three times and incubated for 45 min at
room temperature with rabbit anti-CryAB (1:100 in PBS; made at Uni-
versity of Texas Southwestern) and a mouse monoclonal anti-Hsp25
antibody (1:25 in PBS; Sigma H-0273). Following three washes, the
tissue sections were incubated for 45 min at room temperature with
the following secondary antibodies each at a 1:100 dilution: 1) goat
anti-rabbit Alexa 633 (see above) to detect CryAB and 2) donkey
anti-mouse Alexa 555 (Molecular Probes A31570) to detect Hsp25.
The slides were washed three times in PBS and mounted, observed,
and photographed as described above.
Statistics
Statistics were performed using independent sample t tests, with the
p values adjusted for six pair-wise comparisons using Finner’s multiple
comparison procedure (Finner, 1993). Data were expressed as mean ±
SD for > 6 mice in each group. p < 0.05 was considered significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, two tables, and six figures and can be
found with this article online at http://www.cell.com/cgi/content/full/
130/3/427/DC1/.
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